leadf
logo-loader
viewProactive Group

Insmed rockets after successful phase III study of rare lung disorder drug

The trial found that almost a third of patients treated with Alis and the standard treatment saw a statistical significance in bacteria density by the sixth month

lungs
NTM lung infections are rare but serious and are characterised by fever, weight loss and night sweats

Shares in Insmed Incorporated (NASDAQ:INSM) more than double on Tuesday Morning after the phase III trial of its Alis rare lung disorder therapy met its primary endpoint.

Shortly after the markets opened, Insmed shares climbed 118% to US$26.72.

The late-stage study tested the effectiveness of the drug on 336 patients with resistant nontuberculous mycobacterial (NTM) lung infections.

Insmed said the trial found that almost a third of patients treated with Alis and the standard treatment saw a statistical significance in bacteria density by the sixth month.

That compared with just 9% of patients who were given the standard treatment on its own.

The NASDAQ-listed firm said it now plans to pursue accelerated approval for the therapy which was previously granted breakthrough therapy designation and fast track status by the US Food and Drug Administration.

NTM lung infections are caused by a type of bacteria often found on soil as well as water. It is a rare and serious disease that has symptoms such as fever, weight loss, cough and blood in mucus.

Currently there is no approved treatment for it and potential therapies fail on a relatively frequent basis.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Loop Insights getting ready to rumble as platform wallet being used by the...

Loop Insights (CVE: MTRX- OTCQB: RACMF) CEO Rob Anson joined Steve Darling from Proactive with big news that Loop's Wallet pass platform will engage global boxing fans during the WBC super-middleweight championship fight, featuring champion Saul "Canelo" Alvarez and challenger Avni...

22 hours, 42 minutes ago

2 min read